NEUEXCELL Trademark

Trademark Overview


On Friday, October 22, 2021, a trademark application was filed for NEUEXCELL with the United States Patent and Trademark Office. The USPTO has given the NEUEXCELL trademark a serial number of 97087345. The federal status of this trademark filing is SECOND EXTENSION - GRANTED as of Tuesday, March 5, 2024. This trademark is owned by NeuExcell Therapeutics Inc.. The NEUEXCELL trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceuticals for treating Alzheimer's Disease, Parkinson's Disease, amyotrophic lateral sclerosis (ALS), Huntington's Disease, epilepsy, spinal cord injury, stroke, cerebral aneurysm, traumatic brain injury, concussion, a tumor, cancer, inflammation, viral and baterial infections, ataxia, brain atrophy, spinal cord atrophy, multiple sclerosis, traumatic spinal cord injury, ischemic or hemorrhagic myelopathy (myelopathy), global ischemia, hypoxic ischemic encephalopathy, embolism, fibrocartilage embolism myelopathy, thrombosis, nephropathy, chronic inflammatory disease, meningitis, and cerebral venous sinus thrombosis
neuexcell

General Information


Serial Number97087345
Word MarkNEUEXCELL
Filing DateFriday, October 22, 2021
Status731 - SECOND EXTENSION - GRANTED
Status DateTuesday, March 5, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 14, 2023

Trademark Statements


Goods and ServicesPharmaceuticals for treating Alzheimer's Disease, Parkinson's Disease, amyotrophic lateral sclerosis (ALS), Huntington's Disease, epilepsy, spinal cord injury, stroke, cerebral aneurysm, traumatic brain injury, concussion, a tumor, cancer, inflammation, viral and baterial infections, ataxia, brain atrophy, spinal cord atrophy, multiple sclerosis, traumatic spinal cord injury, ischemic or hemorrhagic myelopathy (myelopathy), global ischemia, hypoxic ischemic encephalopathy, embolism, fibrocartilage embolism myelopathy, thrombosis, nephropathy, chronic inflammatory disease, meningitis, and cerebral venous sinus thrombosis
Pseudo MarkNEURO EXCEL

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, November 8, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameNeuExcell Therapeutics Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressState College, PA 16803

Party NameNeuExcell Therapeutics Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressState College, PA 16803

Trademark Events


Event DateEvent Description
Wednesday, March 6, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, March 5, 2024SOU EXTENSION 2 GRANTED
Tuesday, March 5, 2024SOU EXTENSION 2 FILED
Tuesday, March 5, 2024SOU TEAS EXTENSION RECEIVED
Friday, July 28, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, July 26, 2023SOU EXTENSION 1 GRANTED
Wednesday, July 26, 2023SOU EXTENSION 1 FILED
Wednesday, July 26, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, April 11, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, February 14, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, February 14, 2023PUBLISHED FOR OPPOSITION
Wednesday, January 25, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, January 12, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, January 6, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, January 6, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, January 6, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, August 1, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, August 1, 2022NON-FINAL ACTION E-MAILED
Monday, August 1, 2022NON-FINAL ACTION WRITTEN
Monday, August 1, 2022ASSIGNED TO EXAMINER
Monday, November 8, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, October 26, 2021NEW APPLICATION ENTERED